{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:08:47Z","timestamp":1791576527502,"version":"4.3.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2016,7,15]],"date-time":"2016-07-15T00:00:00Z","timestamp":1468540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,7,15]],"date-time":"2016-07-15T00:00:00Z","timestamp":1468540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1038\/leu.2016.190","type":"journal-article","created":{"date-parts":[[2016,7,15]],"date-time":"2016-07-15T06:46:52Z","timestamp":1468565212000},"page":"2342-2350","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2\/ASXL1\/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis"],"prefix":"10.1038","volume":"30","author":[{"given":"M","family":"Jawhar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Schwaab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Hausmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Clemens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Naumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Henzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H-P","family":"Horny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Sotlar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S O","family":"Schoenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N C P","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Fabarius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W-K","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Valent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Metzgeroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,15]]},"reference":[{"key":"BFleu2016190_CR1","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","volume":"37","author":"P Valent","year":"2007","unstructured":"Valent P, Akin C, Escribano L, Fodinger M, Hartmann K, Brockow K et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007; 37: 435\u2013453.","journal-title":"Eur J Clin Invest"},{"key":"BFleu2016190_CR2","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","volume":"25","author":"P Valent","year":"2001","unstructured":"Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001; 25: 603\u2013625.","journal-title":"Leuk Res"},{"key":"BFleu2016190_CR3","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/ajh.23459","volume":"88","author":"A Pardanani","year":"2013","unstructured":"Pardanani A . Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management. Am J Hematol 2013; 88: 612\u2013624.","journal-title":"Am J Hematol"},{"key":"BFleu2016190_CR4","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1056\/NEJMra1409760","volume":"373","author":"TC Theoharides","year":"2015","unstructured":"Theoharides TC, Valent P, Akin C . Mast cells, mastocytosis, and related disorders. New Engl J Med 2015; 373: 163\u2013172.","journal-title":"New Engl J Med"},{"key":"BFleu2016190_CR5","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/ajh.23931","volume":"90","author":"A Pardanani","year":"2015","unstructured":"Pardanani A . Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management. Am J Hematol 2015; 90: 250\u2013262.","journal-title":"Am J Hematol"},{"key":"BFleu2016190_CR6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00277-013-1964-1","volume":"93","author":"P Erben","year":"2014","unstructured":"Erben P, Schwaab J, Metzgeroth G, Horny HP, Jawhar M, Sotlar K et al. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. Ann Hematol 2014; 93: 81\u201388.","journal-title":"Ann Hematol"},{"key":"BFleu2016190_CR7","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jmoldx.2010.10.004","volume":"13","author":"T Kristensen","year":"2011","unstructured":"Kristensen T, Vestergaard H, Moller MB . Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay. J Mol Diagn 2011; 13: 180\u2013188.","journal-title":"J Mol Diagn"},{"key":"BFleu2016190_CR8","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/path.2677","volume":"220","author":"K Sotlar","year":"2010","unstructured":"Sotlar K, Colak S, Bache A, Berezowska S, Krokowski M, Bultmann B et al. Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD). J Pathol 2010; 220: 586\u2013595.","journal-title":"J Pathol"},{"key":"BFleu2016190_CR9","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1182\/blood-2013-04-496448","volume":"122","author":"J Schwaab","year":"2013","unstructured":"Schwaab J, Schnittger S, Sotlar K, Walz C, Fabarius A, Pfirrmann M et al. Comprehensive mutational profiling in advanced systemic mastocytosis. Blood 2013; 122: 2460\u20132466.","journal-title":"Blood"},{"key":"BFleu2016190_CR10","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1038\/leu.2015.4","volume":"29","author":"M Jawhar","year":"2015","unstructured":"Jawhar M, Schwaab J, Schnittger S, Sotlar K, Horny HP, Metzgeroth G et al. Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event. Leukemia 2015; 29: 1115\u20131122.","journal-title":"Leukemia"},{"key":"BFleu2016190_CR11","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/leu.2015.284","volume":"30","author":"M Jawhar","year":"2016","unstructured":"Jawhar M, Schwaab J, Schnittger S, Meggendorfer M, Pfirrmann M, Sotlar K et al. Additional mutations in SRSF2, ASXL1 and\/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis. Leukemia 2016; 30: 136\u2013143.","journal-title":"Leukemia"},{"key":"BFleu2016190_CR12","unstructured":"Horny HP Akin C, Metcalfe DD, Swerdlow SH, Campo E, Harris NL, et al. World Health Organization (WHO) Classification of Tumours. Mastocytosis (Mast Cell Disease). Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues, vol. 2. IARC Press: Lyon, France, 2008, pp 54\u201363."},{"key":"BFleu2016190_CR13","doi-asserted-by":"publisher","first-page":"3842","DOI":"10.1002\/cncr.24440","volume":"115","author":"A Tefferi","year":"2009","unstructured":"Tefferi A, Thiele J, Vardiman JW . The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer 2009; 115: 3842\u20133847.","journal-title":"Cancer"},{"key":"BFleu2016190_CR14","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"JE Sokal","year":"1984","unstructured":"Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE et al. Prognostic discrimination in \"good-risk\" chronic granulocytic leukemia. Blood 1984; 63: 789\u2013799.","journal-title":"Blood"},{"key":"BFleu2016190_CR15","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","volume":"118","author":"J Hasford","year":"2011","unstructured":"Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 2011; 118: 686\u2013692.","journal-title":"Blood"},{"key":"BFleu2016190_CR16","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","volume":"90","author":"J Hasford","year":"1998","unstructured":"Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998; 90: 850\u2013858.","journal-title":"J Natl Cancer Inst"},{"key":"BFleu2016190_CR17","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. New Engl J Med 2012; 366: 799\u2013807.","journal-title":"New Engl J Med"},{"key":"BFleu2016190_CR18","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","volume":"122","author":"F Cervantes","year":"2013","unstructured":"Cervantes F, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Sirulnik A, Stalbovskaya V et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 2013; 122: 4047\u20134053.","journal-title":"Blood"},{"key":"BFleu2016190_CR19","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.3324\/haematol.2014.119545","volume":"100","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotlib J, Cervantes F, Mesa RA et al. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica 2015; 100: 1139\u20131145.","journal-title":"Haematologica"},{"key":"BFleu2016190_CR20","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","volume":"122","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi AM et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood 2013; 122: 1395\u20131398.","journal-title":"Blood"},{"key":"BFleu2016190_CR21","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1182\/blood-2012-09-458521","volume":"121","author":"J Gotlib","year":"2013","unstructured":"Gotlib J, Pardanani A, Akin C, Reiter A, George T, Hermine O et al. International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood 2013; 121: 2393\u20132401.","journal-title":"Blood"},{"key":"BFleu2016190_CR22","first-page":"1163","volume":"22","author":"JM Mican","year":"1995","unstructured":"Mican JM, Di Bisceglie AM, Fong TL, Travis WD, Kleiner DE, Baker B et al. Hepatic involvement in mastocytosis: clinicopathologic correlations in 41 cases. Hepatology 1995; 22: 1163\u20131170.","journal-title":"Hepatology"},{"key":"BFleu2016190_CR23","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0145-2126(03)00259-5","volume":"28","author":"AW Hauswirth","year":"2004","unstructured":"Hauswirth AW, Simonitsch-Klupp I, Uffmann M, Koller E, Sperr WR, Lechner K et al. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leuk Res 2004; 28: 249\u2013257.","journal-title":"Leuk Res"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2016190.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2016190","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2016190.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T16:17:50Z","timestamp":1648743470000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2016190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,15]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["BFleu2016190"],"URL":"https:\/\/doi.org\/10.1038\/leu.2016.190","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,15]]},"assertion":[{"value":"3 February 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}